Zydus acquires UK's LiqMeds Group

Zydus Lifesciences Limited, a global lifesciences company, has announced the acquisition of the UK-based LiqMeds Group of companies. This strategic move is facilitated through Zydus Pharmaceuticals UK Limited, its wholly owned subsidiary. LiqMeds specializes in the development, manufacturing, and supply of oral liquid products for global markets, currently distributed through partners. A key subsidiary, LM Manufacturing Limited (LMML), operates an oral liquids manufacturing facility in Weedon, Northampton, UK, catering to the US and UK markets.

The acquisition involves an upfront payment of GBP 68 million by Zydus, with additional annual earn-outs until 2026 contingent on achieving predetermined milestones. This transaction is expected to yield earnings per share (EPS) accretion for Zydus right from the first year of acquisition.

Dr. Sharvil Patel, Managing Director of Zydus Lifesciences Limited, emphasized the significance of the liquid oral market, citing its substantial growth potential and its ability to address unmet medical needs, especially for geriatric and pediatric patients. He underscored the role of oral liquid formulations in enhancing convenience and treatment compliance in line with the company's patient-centric approach.